Resultados 1-2 de 2
Crítica de los usuarios - Marcar como inapropiado

The Tivozanib as RCC first-line treatment of drug
The concern may be used as first-line treatment of advanced renal cell carcinoma (RCC) drugs Tivozanib called TiVo-1 of the Phase III clinical
study results will be announced in the first quarter of 2012. Tivozanib is an oral for all three vascular endothelial growth factor receptor inhibitors. Tivozanib in advanced RCC patients treated with disease progression-free survival (PFS) in Phase II clinical studies of up to 11.7 months, by nephrectomy in patients with renal cell carcinoma, Tivozanib treatment PFS was 14.8 months. The current the RCC first-line therapy developed by Pfizer sunitinib malate Nigeria (sunitinib malate, Sutent) in de novo renal clear cell RCC PFS was 11 months. At the same time, the safety evaluation study found with other vascular endothelial growth factor receptor inhibitor therapy compared tivozanib significantly reduce non-target toxicity. Insulin III is expected major adverse reaction of clinical drug results in 2012 submitted a new drug application will support this product.
<a href="">Tivozanib</a> jointly developed by AVEO Pharmaceuticals and Astellas Pharma, 1 week ago the two companies jointly issued the TIVO-1 trial progress. The report said Tivozanib positive result is obtained in the Phase III clinical trials, the test terminal point target renal cell carcinoma patients without disease progression-free survival better than the control group drug sorafenib.
Medchemexpress Can provide the above product,its website:<a href=""></a>
<a href="">BAY 61-3606 dihydrochloride</a>
<a href="">E-3810</a>
<a href="">BAY 61-3606</a>
<a href="">Cabozantinib S-malate</a>
<a href="">Pazopanib</a>
<a href="">Axitinib</a>
<a href="">OSI-930</a>
<a href="">Cediranib</a>
<a href="">MP470</a>
<a href="">Motesanib Diphosphate</a>

Crítica de los usuarios - Marcar como inapropiado

4 estrellas - 0
3 estrellas - 0
2 estrellas - 0
1 estrella - 0

Comentarios editoriales - 0
Comentarios de usuarios - 2